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 2 
SUMMARY 3 
Diabetes mellitus (DM) and pancreatitis are two distinct diseases encountered commonly in small 4 
animal practice. Whilst the clinical signs of DM are usually unmistakeable, a firm diagnosis of 5 
pancreatitis can prove more elusive, as clinical signs are often variable. Over the past 10-15 years, 6 
despite the fact that the clinical signs of DM are remarkably consistent, it has become more 7 
apparent that the underlying pathology of DM in dogs and cats is heterogeneous, with exocrine 8 
pancreatic inflammation accompanying DM in a number of cases. However, the question remains as 9 
to whether the DM causes the pancreatitis or whether, conversely, the pancreatitis leads to DM - as 10 
there is evidence to support both scenarios. The concurrence of DM and pancreatitis has clinical 11 
implications for case management as such cases may follow a more difficult clinical course, with 12 
their glycaemic control being ‘brittle’ as a result of variation in the degree of pancreatic 13 
inflammation. Problems may also arise if abdominal pain or vomiting lead to anorexia. In addition, 14 
diabetic cases with pancreatitis are at risk of developing exocrine pancreatic insufficiency in the 15 




Pancreatitis and diabetes mellitus (DM) have been reported to occur concurrently in many species – 20 
ranging from humans (Larsen 1993), to dogs and cats (Hess and others 2000, Rand and others 2004), 21 
to a cow (Doherty and others 1998), a horse (Jeffrey 1968) and a sea lion (Meegan and others 2008). 22 
It is more than 100 years since the relationship between DM and pancreatitis was first described in 23 
the scientific literature (Opie 1901), yet it is still not clear which disease occurs first i.e. whether the 24 
DM is a cause or a consequence of the pancreatic inflammation (Cook and others 1993, Zini and 25 
others 2010b). The aim of this review is to examine current knowledge of the pathogenesis of both 26 
DM and pancreatitis in cats and dogs, and to examine the evidence for DM leading to pancreatitis or 27 
vice versa. There is of course a third option, where the two diseases are simply concurrent co-28 
incidentally, but the close anatomical relationship between the exocrine and endocrine tissues of 29 
the pancreas and the increased prevalence of pancreatitis in diabetic dogs (Hess and others 2000) 30 
and cats (Goossens and others 1998) compared to that in the non-diabetic canine and feline 31 
population would suggest that this is not the case.  32 
Prior to attempting to evaluate causality in the relationship between DM and pancreatitis, it is first 33 
necessary to review what is known about the pathogenesis of the two conditions. 34 
Pathogenesis of Canine DM 35 
Canine DM is usually the result of insulin deficiency and a classification scheme has been described, 36 
illustrated in Table 1 (Catchpole and others 2005, Catchpole and others 2008). There are several 37 
classification schemes for human DM, but in broad terms, type 1 and type 2 DM are the most 38 
commonly recognised conditions. Type 1 DM, accounting for approximately 10% of human diabetic 39 
patients, is characterised by pancreatic beta cell autoimmunity, insulin deficiency and disease onset 40 
in childhood. In contrast, type 2 disease is commonly associated with obesity and is characterised by 41 
insulin resistance and onset during adulthood.  As it is a disease of insulin deficiency, canine DM 42 
historically has been regarded as most similar to human type 1 DM. 43 
The prevalence of canine DM in the UK is estimated at 0.32% (Davison and others 2005). In some 44 
cases insulin deficiency may be preceded by a phase of insulin resistance, but by the time of 45 
diagnosis, most dogs are unable to synthesise and secrete adequate amounts of endogenous insulin 46 
from the pancreatic beta cells in response to hyperglycaemia (Hoenig 2002, Rand and others 2004). 47 
Certain breeds are predisposed to the disease such as the Samoyed, Tibetan terrier and Cairn terrier 48 
whereas others have a reduced risk such as the boxer, German shepherd dog and the golden 49 
retriever (Davison and others 2005). Many genetic variants have been associated with risk of DM in 50 
the dog, mostly within genes involving innate and adaptive immune responses (Kennedy and others 51 
2006, Short and others 2009, Catchpole and others 2012). The fact that many reported diabetes-52 
associated genetic variants are breed-specific highlights the possibility that the underlying 53 
mechanism(s) for the development of DM may differ between breeds.   54 
A small number of cases of canine DM are diagnosed in young animals less than 6 months of age 55 
(Atkins and others 1979), and these are considered to be congenital in origin. Usually these cases do 56 
not suffer exocrine pancreatic disease so the pathology is likely to be beta-cell specific.  57 
The insulin resistance that precedes diagnosis in an estimated 20-40% of adult canine DM cases may 58 
be caused by exogenous corticosteroid or progestagen treatment or endocrinopathies such as 59 
hyperadrenocorticism (Hess and others 2000). In addition, by a physiological process unique to the 60 
canine species, insulin resistance severe enough to culminate in DM may arise in the progesterone-61 
dominated phase of dioestrus in entire females, during which growth hormone  production by the 62 
mammary glands also contributes to poor glucose tolerance and dioestrus DM (Selman and others 63 
1994, Poppl and others 2012).   64 
Chronic hyperglycaemia in dogs has been shown to result in permanent beta cell damage (Imamura 65 
and others 1988), which is likely to contribute to the fact that almost without exception, diabetic 66 
dogs are fully dependent on insulin from the time of diagnosis. Whilst some studies imply that 67 
obesity may also contribute to insulin resistance in dogs (Mattheeuws and others 1984, 68 
Tvarijonaviciute and others 2012), the evidence for obesity being a risk factor in the development of 69 
canine DM is limited (Klinkenberg and others 2006). It is interesting to note, however, in the context 70 
of this review, that obesity is also a risk factor for pancreatitis in dogs, and that elevated post 71 
prandial triglyceride concentrations have been associated with increased markers of pancreatic 72 
inflammation in obese dogs (Verkest and others 2012) and miniature schnauzers (Xenoulis and 73 
others 2010) .  74 
However, not every dog that experiences insulin resistance develops hyperglycaemia. It is possible 75 
that breed-related differences in beta cell pancreatic reserve exist and it is also possible that 76 
hyperglycaemia may only develop in such circumstances in those dogs who have previously 77 
experienced a primary beta cell insult. 78 
Diabetes mellitus associated with pancreatitis may account for 28-40% of cases of canine DM 79 
(Alejandro and others 1988, Hess and others 2000). Clinical signs may not differ greatly from other 80 
forms of DM, although it is possible that classic signs of acute pancreatitis (AP) may be seen in 81 
addition to the characteristic polyuria, polydipsia, glycosuria and weight loss DM signs. For example 82 
some diabetic dogs with concurrent pancreatitis may present with abdominal pain, vomiting and 83 
anorexia – which is in particular contrast to the usually voracious appetite of diabetic cases. It is also 84 
of note that a recent study suggested that 41% of canine cases with diabetic ketoacidosis (DKA) have 85 
biochemical and / or clinical evidence of AP (Hume and others 2006), implying that one may 86 
contribute to the other. Although awareness of pancreatitis in canine DM is increasing, in some DM 87 
cases pancreatitis may still go unrecognised, especially those with concurrent DKA. This is because 88 
clinical signs of pancreatitis can be subtle and non-specific, especially in its chronic form and may be 89 
attributed by the clinician to the DKA itself.  90 
The remaining cases of canine DM are suspected to be associated with beta cell autoimmunity, 91 
similar to Type 1 DM in humans (Elie and Hoenig 1995).  Serological evidence of reactivity to 92 
pancreatic autoantigens  (Haines and Penhale 1985, Hoenig and Dawe 1992) such as GAD65, IA-2 93 
(Davison and others 2008b) and proinsulin (Davison and others 2011) has been documented in a 94 
number of recently diagnosed canine diabetic cases, but more than 50% of diabetic dogs studied 95 
were negative for autoantibodies, reinforcing the heterogeneous nature of the underlying 96 
pathogenesis of canine DM. The ‘trigger’ for autoimmunity in both humans and dogs is not clear, 97 
although many genetic and environmental factors are known to contribute to autoimmune disease. 98 
Although exocrine pancreatic inflammation is not a common feature or trigger of human type 1 99 
disease,  in dogs it has been proposed that pancreatitis may lead to DM via ‘bystander’ beta cell 100 
damage, resulting in the release of protein antigens usually ‘hidden’ from the immune system and 101 
the initiation of beta cell autoreactivity (Hoenig 2002). 102 
Autoimmune (Type 1) DM in humans is characterised by lymphocytic infiltration of pancreatic islets 103 
(insulitis), which is not a common feature of canine DM, although insulitis was reported in pancreatic 104 
biopsies of 6 of 18 diabetic dogs in one study (Alejandro and others 1988). It is unfortunate that 105 
large scale pathological studies of canine pancreas at the time of diagnosis are lacking, as such data 106 
might help to answer the ‘cause or effect’ question about DM. However, where data have been 107 
published, a mixed inflammatory picture in early disease is seen (Gepts and Toussaint 1967), 108 
followed by complete islet destruction as DM progresses.  In the context of this review, it is 109 
interesting to note that in one study, 5 of the 18 diabetic dogs where the pancreas was examined 110 
were reported to have generalised pancreatic inflammation, affecting both endocrine and exocrine 111 
tissue (Alejandro and others 1988). 112 
Pathogenesis of Feline DM 113 
Feline DM has an estimated UK prevalence of 1 in 230 cats (McCann and others 2007) and in 114 
contrast to canine DM is usually characterised by insulin resistance rather than absolute insulin 115 
deficiency (Rand and others 2004). The disease has a multifactorial aetiology which includes genetic 116 
factors and environmental influences such as obesity and physical inactivity (McCann and others 117 
2007, Slingerland and others 2009, Backus and others 2010), but the exact underlying cause is 118 
unclear as not all obese cats become diabetic. Feline DM appears to be more common with 119 
increasing age, and certain breeds such as the Burmese cat are predisposed, emphasising  the 120 
genetic component to risk (McCann and others 2007, Lederer and others 2009). The recent increase 121 
in prevalence, however, is likely to be related to environmental factors (Prahl and others 2007). 122 
Other diseases can lead to DM in non-obese cats either directly via beta cell damage such as 123 
pancreatic neoplasia (Linderman and others 2012), and pancreatitis (Mansfield and Jones 2001b), or 124 
via insulin resistance e.g. acromegaly (Niessen 2010) or hyperadrenocorticism (Neiger and others 125 
2004).  In addition, overt DM may be triggered by drug therapy with pharmacological agents which 126 
antagonise insulin e.g. corticosteroids or progestagens. 127 
Overt DM in cats usually results from a combination of impaired insulin secretion from the 128 
pancreatic beta cells in addition to peripheral insulin resistance (Rand and others 2004). Pancreatitis 129 
may contribute to both these aspects as the local environment may impact directly on beta cell 130 
function and in addition, inflammation is known to cause peripheral tissue insulin resistance 131 
(Shoelson and others 2006). Most cats are thought to undergo a pre-diabetic glucose-intolerant 132 
phase before the islets are unable to keep up with the extra demand for insulin created by insulin 133 
resistance in the tissues (Osto and others 2012).  134 
Eighty to ninety five percent of feline DM cases have been classified as similar to human type 2 DM 135 
(Rand 1999, O'Brien 2002) based on clinical and histological findings. The term ‘glucose toxicity’ is 136 
used to describe the damage to pancreatic islets as the result of persistent hyperglycaemia (Rand 137 
1999, Osto and others 2012) – and although this may result in permanent damage or death of the 138 
cell, this typically does not lead to an inflammatory response because cell death occurs by apoptosis 139 
(programmed cell death) rather than necrosis (Majno and Joris 1995). 140 
The phenomenon of a remission or ‘honeymoon’ phase once a diabetic cat is treated with insulin 141 
occurs because, in contrast to dogs, who are unlikely to have any islets left at the time of diagnosis, 142 
feline diabetic cases usually have impaired islet function rather than absolute loss in beta cell 143 
numbers at diagnosis. Hence diabetic remission, where it occurs, is the result of beta cell recovery as 144 
the blood glucose is controlled by exogenous insulin (Rand and Marshall 2005). Recent studies 145 
suggest that this may be facilitated by a restricted carbohydrate diet (Kirk 2006, Coradini and others 146 
2011) and intensive insulin therapy to maintain blood glucose concentration within tight limits. 147 
Sustained experimental hyperglycaemia in cats (but not hyperlipidaemia) leads to early, severe beta 148 
cell dysfunction and beta cell loss via apoptosis (Zini and others 2009). This means that if irreversible 149 
beta cell damage has occurred before or during the hyperglycaemic phase in a patient, apoptotic 150 
beta cell death will lead to failure of the patient to enter diabetic remission.  It is not clear whether 151 
diabetic remission is less likely to be achieved in cats with concurrent pancreatitis (Zini and others 152 
2010a), but being aware of the presence of this additional complication will allow pain relief and 153 
other treatment to be provided as necessary which is likely to improve the welfare of the patient.  154 
Pathophysiology of acute and chronic pancreatitis in dogs 155 
Pancreatitis specifically describes inflammation of the exocrine tissues of the pancreas, but in 156 
contrast to humans, no universally accepted classification system exists in veterinary medicine 157 
(Ruaux and Atwell 1998, Newman and others 2006, Mansfield 2012a, Watson 2012).  Clinically, the 158 
presentation may be acute, with some cases suffering recurrent acute episodes, or chronic, 159 
potentially resulting in pancreatic fibrosis. It is therefore possible that AP might cause transient 160 
insulin deficiency, whereas chronic pancreatitis (CP) could lead to permanent loss of beta cells.  161 
The exocrine tissue comprises 95% of the pancreas and surrounds the endocrine tissue, which is 162 
arranged in the islets of Langerhans, composed of insulin-secreting beta cells, glucagon-secreting 163 
alpha cells and somatostatin-secreting delta cells. Although pancreatitis is common, lesions in the 164 
exocrine pancreas evident at a histological level are much more frequent than gross lesions in dogs 165 
(Newman and others 2006). It must also be remembered that much of the current knowledge of the 166 
pathophysiology of pancreatitis in dogs and cats is extrapolated from experimental studies, so a 167 
degree of caution is required in its interpretation. 168 
Several ‘safeguards’ are in place to ensure that the highly damaging pancreatic enzymes synthesised 169 
and secreted by the exocrine cells do not damage the delicate pancreatic tissues in humans and 170 
other species (Mansfield 2012b), such as the storage of enzymes as inactive zymogen precursors 171 
(Rinderknecht 1986), physical separation of the stored enzyme from the rest of the cell in granules, 172 
as well as pancreas-derived secretory trypsin inhibitors and  circulating anti-proteases in the blood 173 
to prevent the inappropriate conversion of trypsinogen to trypsin (Laskowski and Kato 1980).  174 
These safeguards fail in pancreatitis, allowing activation of trypsin and other proteases within the 175 
pancreas itself. This is thought to be a key step in the initiation of the disease, leading to a cascade of 176 
local damage and inflammation (Mansfield 2012b).  177 
As previously mentioned, when pancreatic cells die by apoptosis (programmed cell death), there is 178 
little inflammatory response (Majno and Joris 1995). In contrast, however, where pancreatic necrosis 179 
occurs following protease exposure, a much more significant and damaging ‘cytokine storm’ may 180 
follow (Makhija and Kingsnorth 2002). In AP, the cytokines IL-1, IL-6 and TNF-alpha all contribute to 181 
the inflammatory response, as well as encouraging recruitment of white blood cells such as 182 
monocytes to the area.  183 
A single, isolated, acute pancreatic inflammatory event is not likely to cause DM (although this has 184 
occasionally been reported in humans (Raman and others 2011)), but the endocrine tissue is more 185 
likely to become more seriously affected if inflammation and / or clinical signs persist as CP. The 186 
prevalence of CP in the UK canine population has been estimated at 34% (Watson and others 2007), 187 
with a high proportion of cases with chronic pancreatic inflammation documented at necropsy 188 
showing no associated clinical signs in life. A recent study of 61 cases and 100 controls in the USA 189 
suggested that dogs with clinical CP have significantly higher histological scores for pancreatic 190 
necrosis and peri-pancreatic fat necrosis (usually more associated with acute disease) than dogs with 191 
incidental CP, implying they may in fact have acute-on-chronic pancreatitis (Bostrom and others 192 
2013). This supports the necrosis-fibrosis theory of CP which suggests that irreversible damage is 193 
caused by repeated acute insults to the pancreatic tissue.  194 
Certain breeds appear to be predisposed to AP including spaniels, terriers, dachshunds and poodles. 195 
Recent work to examine the breed-related prevalence of CP in post mortem pancreata from first 196 
opinion practice in the UK suggested that histological evidence of CP in dogs is present in 197 
approximately 34% of cadavers, with Cavalier King Charles spaniels (CKCS), collies and boxers being 198 
over represented (Watson and others 2007). Intriguingly, boxers are under-represented in canine 199 
diabetic cohorts (Fall and others 2007).  200 
Definitive diagnosis and classification of pancreatitis has been discussed elsewhere (Cordner and 201 
others 2010), Mansfield and others 2012, (Watson 2012). A presumptive non-invasive diagnosis is 202 
usually made using a combination of history, physical examination and clinical signs, in combination 203 
with measurement of canine pancreatic lipase immunoreactivity (cPLI) (Mansfield and others 2012) 204 
and  / or ultrasonographic examination of the pancreas. 205 
Pathophysiology of acute and chronic pancreatitis in cats 206 
Similar to pancreatitis in dogs, the aetiology  of pancreatitis in cats is also only partially understood 207 
(Xenoulis and Steiner 2008), but what is known of the pathophysiology has been well reviewed 208 
(Bazelle and Watson 2014). The basic protective mechanisms and anatomy of the pancreas are 209 
similar to those described in the dog (Mansfield and Jones 2001a). However, the diagnosis of feline 210 
pancreatitis can be even more challenging than in dogs because clinical signs may be very mild, non-211 
specific and remain unnoticed by the owner (Xenoulis and Steiner 2008), such as partial anorexia or 212 
lethargy (Washabau 2001). This makes it difficult to assess its prevalence in the diabetic and non-213 
diabetic population. Early studies suggested a prevalence of less than 3% (Steiner and Williams 1999) 214 
but more recent histopathological work implies that the prevalence of pancreatic inflammation in 215 
cats is much higher than this – 67% in animals with clinical signs and 45% in clinically healthy cats, 216 
with the majority of these cases having chronic rather than acute inflammatory infiltrates (De Cock 217 
and others 2007). Within the diabetic cat population, the prevalence of pancreatic inflammation 218 
may be even higher still – with evidence of pancreatitis at post mortem examination being described  219 
in 19 out of 27 diabetic cats examined (Goossens and others 1998).  The histopathological features 220 
of feline pancreatitis have been extensively reviewed (Mansfield and Jones 2001a) and vary in 221 
severity and chronicity. Pancreatitis in cats may also be associated with cholangiohepatitis and 222 
inflammatory bowel disease (Caney 2013).  223 
As in dogs, the underlying cause of pancreatitis in cats is not clear, but genetics, infection (e.g. viral, 224 
parasitic), trauma and the presence of other common inflammatory conditions may all contribute to 225 
risk (Xenoulis and Steiner 2008). Diagnosis may be especially challenging in cats as already described, 226 
but a combination of history, clinical examination, diagnostic imaging and feline pancreas specific 227 
lipase (fPLI) measurement is recommended (Forman and others 2004, Xenoulis and Steiner 2008). As 228 
in dogs, CP in cats may eventually result in exocrine pancreatic insufficiency as the enzyme-229 
producing cells are slowly replaced by fibrous tissue (Steiner and Williams 1999).  230 
The relationship between exocrine pancreatic inflammation and DM in human medicine 231 
As illustrated above, canine and feline DM have similar clinical signs but different underlying 232 
pathophysiology. It is therefore conceivable that the role of pancreatitis in each disease will be 233 
different. In dogs, the closest human parallel is type 1 DM and in cats the closest human parallel is 234 
type 2 DM, so the contribution of pancreatitis to both these diseases, and in contrast the potential 235 
contribution of both these diseases to pancreatitis, should be considered. However, there is very 236 
little published evidence of type 1 DM and acute (or chronic) pancreatitis co-existing in human 237 
medicine.  This may be because type 1 DM usually occurs in young children (Hummel and others 238 
2012) and in this age group pancreatitis is usually confined to genetic or traumatic causes, meaning 239 
that the majority of human diabetes – pancreatitis studies relate to type 2 DM. There is clear 240 
evidence that patients with longstanding type 1 DM develop pancreatic atrophy (Williams and 241 
others 2012), but to the author’s knowledge, there are no clear human studies linking type 1 DM to 242 
risk of pancreatitis later in life.  243 
Not surprisingly, human pancreatitis has many underlying causes, with acute disease commonly 244 
being associated with toxaemia, gallstones, trauma, medication or infection. One difference 245 
between humans and veterinary species is that bacterial translocation from the gut is a well-246 
recognised and important source of infection in human AP, and may result in pancreatic 247 
abscessation (Schmid and others 1999). In human AP, clinical signs include severe abdominal pain, 248 
fever, nausea, vomiting or dehydration and in those cases where pancreatic necrosis occurs, the 249 
disease may be fatal (Cruz-Santamaria and others 2012). 250 
The most common cause of CP in humans is chronic alcohol consumption but genetic predisposition, 251 
autoimmune disease, or other diseases such as cystic fibrosis may also chronically impede exocrine 252 
pancreatic function and lead to pancreatic inflammation. Chronic pancreatitis shows similar clinical 253 
signs to acute disease but they are generally less severe and more prolonged. It is of particular note 254 
that in human type 2 DM, the risk of CP is two to three times higher than that in healthy subjects 255 
(Girman and others 2010) and a recent meta-analysis indicated that type 2 diabetic patients are also 256 
at increased risk of AP (Yang and others 2013).  257 
This raises the question of why human type 2 DM patients are prone to pancreatitis – does the 258 
diabetic state itself contribute to the onset of pancreatic inflammation? This possibility is raised by a 259 
meta-analysis in which diabetic individuals had a 92% increased risk of development of CP, 260 
independent of other risk factors such as alcohol use, gallstones and hyperlipidaemia (Xue and 261 
others 2012). Similarly in AP, a meta-analysis reported that insulin resistance and hyperglycaemia 262 
are important factors in the susceptibility of diabetic individuals to AP (Solanki and others 2012). It is 263 
also of potential relevance  that human patients with DM are at a greater risk of particularly severe 264 
AP, even if the DM was not originally associated with pancreatitis at diagnosis (Shen and others 265 
2012). Experimental rodent models of pancreatitis and DM suggest that the presence of 266 
hyperglycaemia can exacerbate AP and suppress regeneration of exocrine tissue (Zechner and others 267 
2012). This implies an important clinical point - that poor glycaemic control may contribute to the 268 
severity of AP and aggravate the progression of the disease. 269 
Although the studies mentioned above highlight the increased risk for pancreatitis in diabetic 270 
patients, the majority of the published evidence points to pancreatitis preceding the DM in humans 271 
i.e. the DM is secondary to the pancreatitis rather than the DM causing pancreatic inflammation 272 
(Kazumi and others 1983, Jap and others 1992, Cavallini and others 1993, Larsen 1993). A recent 273 
meta-analysis suggested that following an episode of AP, a patient has a two-fold increased risk of 274 
developing DM within 5 years (Das and others 2014). This type of DM is classified as neither type 1 275 
nor type 2 DM, but a separate category of “other specific types of DM”.  276 
Diabetes mellitus in human patients with CP is more likely to be found later in the course of the 277 
exocrine pancreatic disease (Singh and others 2012), and similar to canine and feline cases, CP in 278 
humans may ultimately result in malabsorption due to pancreatic insufficiency. This timecourse is 279 
also similar to an obese rodent model of pancreatitis, in which DM develops later during the course 280 
of the disease. It is of particular interest in this model that the pancreatitis can be made less severe 281 
and the onset of DM delayed by dietary restriction (Akimoto and others 2010).  282 
As already discussed for dogs and cats, the exact mechanism by which CP results in DM is likely to be 283 
complex in humans. Studies of cytokine concentrations in pancreatic tissues from CP patients by 284 
flow cytometry demonstrate increased interferon gamma in both diabetic and non-diabetic patients, 285 
a cytokine which has been shown to impede beta cell function and therefore may play a role in DM 286 
associated with CP (Pavan Kumar and others 2012). It is also apparent that patients with concurrent 287 
type 2 DM and CP have an increased risk of developing pancreatic cancer (Brodovicz and others 288 
2012), although no similar correlation has been reported in dogs or cats. 289 
A more rare condition in humans, called Autoimmune Pancreatitis (AIP) is characterised 290 
radiologically by enlargement of the pancreas, narrowing of the pancreatic duct, lymphoplasmacytic 291 
pancreatic infiltrate and classically an elevation of serum IgG4 levels (Kamisawa and others 2010). 292 
This disease is commonly associated with insulin-dependent DM in adults (Ito and others 2011) and 293 
tends to be very responsive to steroid treatment. These patients rarely have the autoantibodies to 294 
islet antigens that characterise classical type 1 DM, although pancreatic histology suggests cellular 295 
islet infiltrates and reduced numbers of beta cells.  The classic autoantigens in AIP are lactoferrins 296 
and carbonic anhydrase II (Hardt and others 2008). The pathophysiology of the DM seen in AIP has 297 
not been fully elucidated but is not thought to be related to non-specific collateral damage from the 298 
pancreatic inflammatory process, but rather a specific immunological effect, thought to be triggered 299 
by the pancreatitis (Miyamoto and others 2012). This would therefore again make the pancreatitis a 300 
cause rather than an effect of the DM and offers an alternative mechanism for immune-mediated 301 
islet destruction. At present, however, IgG4 measurement is not routinely performed in veterinary 302 
medicine, so a companion animal counterpart of AIP has not been identified, although studies are 303 
ongoing and it is possible that certain types of breed-related DM may share pathophysiological 304 
features with AIP. 305 
 306 
The relationship between pancreatitis and DM in dogs 307 
In a study of 80 dogs with severe AP, 29 dogs had concurrent DM (Papa and others 2011), making 308 
the prevalence of DM much higher in this population than in dogs without AP. In a recent UK 309 
retrospective study of DM in first opinion practice (Mattin and others 2014), diabetic dogs diagnosed 310 
with pancreatitis also had a higher hazard of death. Having reviewed the underlying causes of both 311 
diseases, and the relationship between these conditions in humans, the question remains, does 312 
canine pancreatitis cause DM or can canine DM result in pancreatitis? The intuitive answer is that 313 
pancreatitis is likely to occur first, with the beta cells succumbing to bystander damage, either by 314 
non-specific inflammation or the triggering of an autoimmune process and epitope spreading. 315 
However, the increased risk of pancreatitis in human diabetic patients also suggests that pancreatitis 316 
could theoretically be a consequence of DM, so it may be the case that both diseases may have a 317 
negative impact on each other.   318 
It is possible too that a more broad, over-arching mechanism may be at work. In another recent 319 
study, canine CP cases were significantly more likely to have an endocrine disease than dogs without 320 
pancreatitis, specifically DM or hypothyroidism (Bostrom and others 2013). It is therefore possible 321 
that the mechanisms for pancreatitis development in both hypothyroidism and DM are similar, 322 
implying that endocrine disease may be contributing to the initiation of the pancreatic inflammation. 323 
One such risk factor, shared between DM and hypothyroidism, may be the high cholesterol resulting 324 
from the endocrinopathy acting as a trigger for pancreatitis, as hyperlipidaemia has been shown to 325 
cause pancreatitis in humans (Tsuang and others 2009) and dogs (Hess and others 1999). However, 326 
it must also be remembered that in dogs, as in humans, there are shared genetic factors for DM and 327 
hypothyroidism so it is also possible that these may be shared with other genetic risk factors for 328 
pancreatitis. Sharing of genetic risk variants does not necessarily imply that one disease causes the 329 
other.   330 
Is there any evidence at the cellular or molecular level that DM may trigger pancreatitis in dogs? 331 
Although the cytokine milieu in human and canine pancreatitis has been investigated (discussed 332 
earlier), very little is known about the local cytokine environment in the pancreatic islets in canine 333 
DM. However, despite the lack of local measurements, some circulating cytokine profiles have been 334 
reported in a study of healthy dogs, dogs with DM and dogs with DKA. The cytokines IL-18 and GM-335 
CSF were elevated in DKA dogs before treatment compared to after successful treatment, and pro-336 
inflammatory factors CXCL8 and MCP-1 were significantly higher in dogs with DM compared to 337 
controls (O'Neill and others 2012). However, 7 of the 9 dogs with DKA in this study also had 338 
pancreatitis, and as IL-18 is a pro-inflammatory cytokine associated with pancreatitis in humans it is 339 
difficult to know if the presence of this cytokine is a cause or consequence of the pancreatitis.  340 
Nonetheless, CXCL8 and MCP-1 are both associated with inflammation, so have the potential to 341 
contribute to pancreatitis.  A more recent study of alterations in innate immunity in dogs associated 342 
with DM also suggested that white blood cells from diabetic cases produce more pro-inflammatory 343 
cytokines in response to stimulation and hypothesised that this may predispose diabetic dogs to 344 
infectious and inflammatory complications (DeClue and others 2012).  345 
Another theoretical trigger for pancreatitis which may be associated with DM in dogs is the potential 346 
for the presence of circulating autoantibodies to pancreatic proteins or anti-insulin antibodies 347 
induced by treatment (Davison and others 2003, Davison and others 2008a) to form immune 348 
complexes in the pancreas. However, this is most likely an academic concern as it has not been 349 
proven in practice. Cats do not appear to suffer from autoimmune pancreatitis  and nor do they 350 
commonly make antibodies to exogenous insulin so this mechanism appears even less likely to occur 351 
in this species (Hoenig and others 2000).  352 
Another particular challenge in establishing which disease occurs first relates to the fact that one 353 
condition may be clinically silent e.g. CP. In a study of 14 confirmed canine cases of CP, the pancreas 354 
only appeared ‘abnormal’ on 56% of ultrasound examinations and the sensitivity of cPLI when 355 
combined with amylase and lipase measurement was 44 to 67% when using a low cut off value. 356 
(Watson and others 2010). At present, it is not routine to test the glucose tolerance of all cases with 357 
AP or CP or to test pancreatic inflammatory markers in all newly diagnosed canine diabetic cases. 358 
Nor, of course are pancreatic biopsies routine in diabetic cases. However, some work has been 359 
undertaken to try to establish the prevalence of defective beta cell function amongst pancreatitis 360 
cases which gives some insight into the order in which the diseases may arise.  361 
Watson and Herrtage (2004) used a glucagon stimulation test to evaluate endocrine pancreatic 362 
reserve in canine cases with clinical pancreatitis. By measuring the insulin and glucose response 363 
following an intravenous glucagon dose, a functional defect in endocrine pancreatic function was 364 
demonstrated in 5 of 6 dogs with pancreatitis, implying that inflammation can impair insulin 365 
secretion from beta cells. This suggests that in cases where the two diseases are concurrent, 366 
pancreatic inflammation may precede DM in dogs.  A similar timeline was seen in a small case series 367 
of 4 dogs with EPI secondary to CP. Two of these dogs developed DM, and this happened after the 368 
diagnosis of CP but before the diagnosis of EPI (Watson 2003). This suggests an order of events 369 
beginning with pancreatitis, moving on to DM and culminating in pancreatic fibrosis and EPI, at least 370 
in some dogs.  This mirrors the findings of recent human studies which suggest that in cases where 371 
DM develops secondary to CP, islet dysfunction occurs first due to the local inflammatory milieu but 372 
clinical DM does not manifest until later, when fibrosis causes islet destruction (Sasikala and others 373 
2012). 374 
The relationship between pancreatitis and DM in cats 375 
One recent study reported that 26 of 40 cats with naturally occurring DM were found to have 376 
elevated lipase concentration at the time of admission to a clinical facility (Zini and others 2010b). 377 
Although elevation in serum lipase is not perfectly sensitive or specific for a diagnosis of pancreatitis, 378 
this study appears to concur with a 1998 study in which 19 of 37 diabetic cats were shown to have 379 
evidence of pancreatic inflammation on post mortem examination (Goossens and others 1998). As 380 
the pathology of DM in cats relates to insulin resistance, which can be caused by a focus of 381 
inflammation within the body, it is not difficult to propose a causal role for pancreatitis in feline DM. 382 
If this is the case, similar mechanisms for islet cell damage to those discussed for canine pancreatitis 383 
may play a role. 384 
However, to counter this argument, the biochemical states of hyperglycaemia and hyperlipidaemia, 385 
as seen in feline DM, have been shown to contribute to inflammatory responses in humans 386 
(Shoelson and others 2007) implying that the metabolic changes in DM may contribute to 387 
pancreatitis developing subsequently. As feline DM is considered to be similar to human type 2 DM, 388 
it is possible that diabetic cats are subject to the same increased risk for pancreatitis as already 389 
described for humans with type 2 DM. One experimental study, designed to investigate the 390 
relationship between hyperglycaemia, hyperlipidaemia and pancreatitis in cats reported that 10 days 391 
of hyperglycaemia increased pancreatic neutrophils, but without causing pancreatic damage, a 392 
finding which was not seen in cats with experimentally induced hyperlipidaemia (Zini and others 393 
2010b). This suggests that hyperglycaemia may play a role in predisposing to feline pancreatitis but 394 
other factors are also involved in the early stages of pancreatic inflammation.  395 
It is also helpful to recognise recent work in human type 2 DM and metabolic syndrome has 396 
demonstrated that obesity and inflammation are directly linked (Shoelson and Goldfine 2009). 397 
Adipose tissue can have a significant influence on metabolism and the immune system via synthesis 398 
and secretion of chemical mediators such as adipokines and adipocytokines (Whitehead and others 399 
2006). This pro-inflammatory environment can in turn lead to recruitment and activation of 400 
inflammatory cells and may also play a role in beta cell damage during hyperglycaemia via cytokines 401 
such as IL-6 and IL-1 beta. If this type of inflammation occurs in obese cats, within the pancreas, then 402 
it is certainly possible that it may act as a trigger for pancreatitis. 403 
A biochemical marker of AP, although not 100% sensitive, feline pancreatic lipase immunoreactivity 404 
was found to be elevated in a different cohort of feline diabetic cases (Forcada and others 2008), 405 
and correlated with serum fructosamine concentration, which may also reflect the relationship 406 
between inflammation and insulin resistance.  407 
Clinical implications of the relationship between pancreatitis and DM 408 
Dogs: Based on the evidence presented here, the balance appears to be slightly in favour of 409 
pancreatitis preceding DM and hence in favour of the exocrine disease contributing to or triggering 410 
the endocrine disease. It is also clear, however, that there are multiple routes to lack of beta cell 411 
function in dogs and pancreatitis is only one potential causal factor. It is still theoretically possible 412 
that, at least in dogs, pancreatitis may develop in response to the hyperglycaemia or 413 
hyperlipidaemia associated with DM, a risk which may be even further exacerbated by the increased 414 
potential for bacterial infection (DeClue and others 2012) and toxaemia in diabetic cases, but this is 415 
difficult to prove. 416 
An important clinical observation is that where pancreatitis and DM do co-exist, the practitioner may 417 
be blinded to the presence of one of these conditions. The prevalence of the two diseases 418 
concurrently in dogs is remarkably high, and it is important to recognise AP or CP as it increases 419 
insulin resistance as well as being significantly correlated with risk of DKA. In addition there is the 420 
long term risk of intermittent ‘flare-ups’ of disease and the potential for glycaemic control to be 421 
complicated in future by the development of exocrine pancreatic insufficiency.  422 
Although pancreatitis can be a difficult diagnosis to make clinically, for the reasons outlined above, 423 
in the author’s opinion, serious consideration should be given to evaluating every diabetic dog, 424 
particularly those who are newly diagnosed or unstable, for exocrine pancreatic disease, for example 425 
by measurement of cPLI. Whilst management of pancreatitis may appear fairly non-specific, - being 426 
based on nutritional support, low fat food, intravenous fluid therapy and analgesia, the knowledge 427 
that a diabetic dog has accompanying exocrine pancreatic inflammation can make a further 428 
significant contribution to the clinical management and prognosis, allowing the owner and 429 
veterinary surgeon to make better informed decisions, improving the animal’s quality of life. 430 
In contrast, however, there is insufficient evidence at present to recommend a glucagon stimulation 431 
test to evaluate endocrine function in every animal with pancreatitis, but it is still important that 432 
cases that are suspected to have pancreatitis should be regularly examined and owners warned of 433 
the potential risks of DM in the future.  434 
Cats: The relationship between obesity / inactivity and DM in cats is undeniable, so regardless of co-435 
existing pancreatitis, weight loss and increased activity, plus an appropriate diet are the most 436 
important factors in helping to prevent many cases of DM in cats.  As discussed however, there is 437 
clearly also an important relationship between insulin resistance and pancreatitis in cats, in which 438 
the pancreatic exocrine tissue inflammation may even be initiated or exacerbated by 439 
hyperglycaemia in some cases. It is therefore important to consider the possibility of pancreatic 440 
inflammation in all diabetic cats, even if they have no history of AP, because hyperglycaemia 441 
resulting from obesity, acromegaly, inflammation or exogenous drug treatment has the potential to 442 
contribute to the development of exocrine pancreatic inflammation. 443 
Where a diagnosis of pancreatitis pre-dates documented hyperglycaemia, it appears likely that 444 
pancreatitis predisposes to the demise of beta cells and contributes to peripheral insulin resistance, 445 
precipitating DM in genetically susceptibly or obese cats. The same principles discussed for dogs 446 
therefore also apply to cats, i.e. ideally the clinician should be consciously aware of both diseases, 447 
and should consider testing newly diagnosed diabetic cats for pancreatitis, especially because clinical 448 
signs may be so subtle and unregulated pancreatic inflammation may have a dramatic and negative 449 
impact on clinical outcome. This is especially true if an intensive protocol to achieve DM remission is 450 
being undertaken, as active pancreatic inflammation and its associated clinical signs, however 451 
subtle, may compromise the effectiveness of this approach. 452 
CONCLUSIONS: 453 
Diabetes mellitus and pancreatitis are both complex diseases, showing many species-specific 454 
features in dogs, cats and humans. As the endocrine and exocrine tissues of the pancreas are so 455 
interlinked, it is not surprising that damage to one or the other has an impact on the surrounding 456 
tissues. The main conclusion that can be drawn is that whilst the most common direction of 457 
progression may be that DM occurs secondary to  pancreatitis, the two disease may still be seen in 458 
the ‘reverse order’ in certain circumstances.  459 
Additionally, DM and pancreatitis may arise by a number of mechanisms but there are particular 460 
environmental triggers and genetic pre-dispositions which make this more likely. Figure 1 illustrates 461 
the ‘circular argument’ of cause and effect, including putative (but not necessarily proven) factors 462 
from each of the two diseases which could increase the risk of the second disease developing.  The 463 
most important message is that clinicians continue to remain aware of the potential for both 464 
diseases to co-exist.  The benefits to the diabetic patient when a serious complication is recognised 465 
and treated, despite it having potentially only subtle clinical signs, will be just as important whether 466 
or not the pancreatitis has arisen as a cause or consequence of the DM. 467 
 468 
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  748 
Table 1 749 
Classification of canine diabetes mellitus (Catchpole and others 2005) 750 
Insulin deficiency diabetes (IDD) 751 
Primary IDD in dogs is characterised by a progressive loss of pancreatic beta cells. The 752 
aetiology of beta cell deficiency/destruction in diabetic dogs is currently unknown but a 753 
number of diseases processes are thought to be involved: 754 
• Congenital beta cell hypoplasia/abiotrophy 755 
• Beta cell loss associated with exocrine pancreatic disease 756 
• Immune-mediated beta cell destruction 757 
• Idiopathic 758 
 759 
Insulin resistance diabetes (IRD) 760 
Primary IRD usually results from antagonism of insulin function by other hormones:  761 
• Dioestrous/gestational diabetes 762 
• Secondary to other endocrine disorders 763 
• Hyperadrenocorticism 764 
• Acromegaly 765 
• Iatrogenic 766 
• Synthetic glucocorticoids 767 
• Synthetic progestagens 768 
• Glucose intolerance associated with obesity might contribute to insulin resistance but is 769 



















Figure 1 – The putative influences of diabetes on pancreatitis and vice versa 789 
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